ArteraAI Prostate
Save to shortlistLast reviewed Oct 31, 2026 against the sources listed on this page · How we review
At a glance
ArteraAI Prostate is a multimodal AI digital pathology test that analyzes digitized prostate biopsy images together with clinical data to provide prognostic and predictive insights for localized…
- FDA:
- De Novo DEN240068
- Epic:
- Not on record
- Named users:
- 1 named in public reports
- Published study:
- Not on record
Description
ArteraAI Prostate is a multimodal AI digital pathology test that analyzes digitized prostate biopsy images together with clinical data to provide prognostic and predictive insights for localized prostate cancer. In August 2025 it received FDA de novo authorization as the first AI tool cleared to give both prognostic and predictive information, including 10-year metastasis risk and likely benefit from specific therapies. It is used at the point of diagnosis in qualified pathology laboratories and is included in NCCN prostate cancer guidelines.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is ArteraAI Prostate FDA cleared?
- The public FDA database has one record that our team matched to ArteraAI Prostate. The most recent is De Novo DEN240068 (ArteraAI Prostate), decided Jul 2025. Check that the cleared use matches how you plan to use it.FDA record DEN240068
- Which health systems use ArteraAI Prostate?
- Linked public reports name one organization: CorePlus. "Who's using this" below lists them all, plus any the maker reports. Ask the vendor for a reference at an organization like yours.CorePlus (Business Wire)
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Not assessed
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
1 organizationOrganizations named in public announcements or by the developer. Inclusion is not an endorsement.
Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.
Get weekly updates for Pathology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
WebsiteFDA database records
- DEN240068 · De Novo · Jul 2025ArteraAI Prostate
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (3)Show
Dated events on this listing's public record, newest first.
Developer
Artera (ArteraAI)
Artera, Inc. (Los Altos, CA)
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →